134:, but have become lost (either by error in a computer tracking system or by being unreachable) at the point of follow-up in the trial. These patients can become lost for many reasons. Without properly informing the investigator associated with the clinical trial, they may have opted to withdraw from the clinical trial, moved away from the particular study site during the clinical trial, become ill and unable to communicate, are missing or are
22:
182:
There are no standards or guidelines that express the process or methods that can be used to attempt to reach patients who have become lost to follow-up. Institutions such as the FDA have taken action over the recovery of or communication with patients lost-to-follow-up. Section 4.3.4 of the ICH E-6
173:
and high rates of patients lost-to-follow-up have many side-effects, including longer clinical research trial periods and more monetary expenditures because extra resources may need to be dedicated to the recruitment efforts.
187:"Although a subject is not obliged to give his/her reason(s) for withdrawing prematurely from a trial, the investigator should make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights."
248:
Akl, Elie A; Briel, Matthias; You, John J; Lamontagne, Francois; Gangji, Azim; Cukierman-Yaffe, Tali; Alshurafa, Mohamad; Sun, Xin; Nerenberg, Kara A; Johnston, Bradley C; Vera, Claudio (2009-06-11).
169:
Aside from partial study data and regulatory issues, patients that are not retained due to being lost-to-follow-up can lead to problems with the progression of any clinical research study. Low
205:
Cleland, John G. F.; Torp‐Pedersen, Christian; Coletta, Alison P.; Lammiman, Michael J. (2004). "A method to reduce loss to follow-up in clinical trials: informed, withdrawal of consent".
163:
162:
scrutiny of the particular study drug, as well as the pharmaceutical company sponsoring the clinical research study. Biased study outcomes also lead to issues of
146:
Patients who become lost to follow-up during a clinical research trial result in many negative effects on the outcome of the trial and on the
39:
150:
sponsoring the clinical research trial. Patients who are lost-to-follow-up lead to incomplete study results, which in turn can put a
105:
86:
58:
43:
65:
159:
330:
72:
32:
54:
147:
313:. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
307:
79:
289:
271:
230:
222:
119:
279:
261:
214:
284:
250:"LOST to follow-up Information in Trials (LOST-IT): a protocol on the potential impact"
249:
170:
131:
324:
218:
308:"Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2)"
21:
155:
275:
226:
266:
293:
234:
154:
on the result of the study as well as a bias on the investigational study
135:
127:
151:
15:
130:
who at one point in time were actively participating in a
183:
Good
Clinical Practice: Consolidated Guidance reads
46:. Unsourced material may be challenged and removed.
158:. A lack of complete results leads to intensified
8:
283:
265:
106:Learn how and when to remove this message
197:
7:
44:adding citations to reliable sources
14:
207:European Journal of Heart Failure
20:
31:needs additional citations for
1:
219:10.1016/j.eheart.2003.12.001
347:
166:standards and compliance.
267:10.1186/1745-6215-10-40
132:clinical research trial
189:
148:pharmaceutical company
185:
40:improve this article
55:"Lost to follow-up"
171:rates of retention
331:Clinical research
124:loss to follow-up
120:clinical research
116:
115:
108:
90:
338:
315:
314:
312:
304:
298:
297:
287:
269:
245:
239:
238:
202:
122:trial industry,
111:
104:
100:
97:
91:
89:
48:
24:
16:
346:
345:
341:
340:
339:
337:
336:
335:
321:
320:
319:
318:
310:
306:
305:
301:
247:
246:
242:
204:
203:
199:
194:
180:
144:
142:Adverse effects
112:
101:
95:
92:
49:
47:
37:
25:
12:
11:
5:
344:
342:
334:
333:
323:
322:
317:
316:
299:
240:
196:
195:
193:
190:
179:
176:
143:
140:
114:
113:
28:
26:
19:
13:
10:
9:
6:
4:
3:
2:
343:
332:
329:
328:
326:
309:
303:
300:
295:
291:
286:
281:
277:
273:
268:
263:
259:
255:
251:
244:
241:
236:
232:
228:
224:
220:
216:
212:
208:
201:
198:
191:
188:
184:
177:
175:
172:
167:
165:
161:
157:
153:
149:
141:
139:
137:
133:
129:
125:
121:
110:
107:
99:
96:November 2020
88:
85:
81:
78:
74:
71:
67:
64:
60:
57: –
56:
52:
51:Find sources:
45:
41:
35:
34:
29:This article
27:
23:
18:
17:
302:
257:
253:
243:
210:
206:
200:
186:
181:
168:
145:
123:
117:
102:
93:
83:
76:
69:
62:
50:
38:Please help
33:verification
30:
213:(1): 1–2.
192:References
156:medication
126:refers to
66:newspapers
276:1745-6215
227:1879-0844
178:Solutions
325:Category
294:19519891
235:15012911
136:deceased
128:patients
285:2706244
118:In the
80:scholar
292:
282:
274:
260:: 40.
254:Trials
233:
225:
82:
75:
68:
61:
53:
311:(PDF)
164:HIPAA
87:JSTOR
73:books
290:PMID
272:ISSN
231:PMID
223:ISSN
152:bias
59:news
280:PMC
262:doi
215:doi
160:FDA
42:by
327::
288:.
278:.
270:.
258:10
256:.
252:.
229:.
221:.
209:.
138:.
296:.
264::
237:.
217::
211:6
109:)
103:(
98:)
94:(
84:·
77:·
70:·
63:·
36:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
